Kewalramani Reshma 4

What Happened

• Reshma Kewalramani, CEO, President and a director of Vertex Pharmaceuticals (VRTX), disposed of 8,297 shares on Feb 10, 2026 at a reported price of $468.41 per share, a total value of about $3,886,398. The filing shows this disposition was a tax-withholding/payment event (transaction code F), not an open-market sale.

Key Details

• Transaction date: 2026-02-10
• Price: $468.41 per share; Shares surrendered: 8,297; Gross value ≈ $3,886,398
• Transaction code: F — payment of exercise price or tax liability via share surrender (withholding)
• Shares owned after the transaction: not disclosed in the supplied filing
• Filing date: 2026-02-12 — filed within the normal two-business-day Form 4 deadline (appears timely)

Context

• This was a tax-withholding/net settlement related to an option exercise or vesting event: the company or broker withheld (surrendered) shares to cover tax obligations. That is a routine administrative disposition and not the same as an open-market sale signaling a directional view. No speculative inference about insider confidence should be drawn from this single withholding event.